A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis
This study will compare how well the study drug works in slowing the progression of kidney disease and how safe the study drug is when compared to placebo in chronic kidney disease patients with metabolic acidosis. The average duration of the study is anticipated to be about 3.5 years.
MoreAdult
Male and female subjects between 18 - 85, inclusive GFR between 20 and 40 ml/min/1.73 m2, inclusive Serum Bicarbonate between 12 and 20 mEq/L, inclusive Systolic blood pressure <160/92
Outcomes Research
Colorado Research Center
Renal Research Center
Jessica Kendrick, MD
Protocol Number: 18-1795
More information available at ClinicalTrials.gov: NCT03710291
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers